RNA transfection

Omega Therapeutics to Participate in the Jefferies London Healthcare Conference

Retrieved on: 
Thursday, November 3, 2022
Investor, OMEGA, Gene expression, Growth, Conference, Therapy, Regenerative medicine, Company, Disease, Cell death, Hair, Omega, RNA transfection, Nasdaq, Flagship Pioneering, Vaccine

CAMBRIDGE, Mass., Nov. 3, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022, at 11:30 a.m. GMT (6:30 a.m.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 3, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022, at 11:30 a.m. GMT (6:30 a.m.
  • A live webcast of the fireside chat will be available on the Investors & Media section of the Company's website at www.omegatherapeutics.com .
  • An archived replay of the fireside chat will be available on the same website for approximately 90 days.
  • Omega Therapeutics, founded by Flagship Pioneering, is a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines.

Telesis Bio to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 8

Retrieved on: 
Wednesday, November 2, 2022
Security (finance), RNA transfection, RNA, DNA, Reading, U.S. Securities and Exchange Commission, SEC, GLOBE, Synthetic biology, Codex, PIN, Invention, Telephone, Technology, Private Securities Litigation Reform Act, Investor, Gibson, Precision medicine, Biology, SAN, Forward-looking statement, Laboratory, Pharmaceutical industry, Telesis

SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2022 financial results on Tuesday, November 8, 2022, after the market closes.

Key Points: 
  • SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2022 financial results on Tuesday, November 8, 2022, after the market closes.
  • The press release and live audio webcast can be accessed via the Investors section of Telesis Bios website at www.codexdna.com .
  • Telesis Bio is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanitys greatest challenges.
  • All trademarks are the property of Telesis Bio (formerly Codex DNA Inc.), For specific trademark information, contact us at [email protected] .

Matinas BioPharma Reports Third Quarter 2022 Financial Results and Highlights Recent Progress

Retrieved on: 
Wednesday, November 2, 2022
MD, DNA, Population, SEC, GLOBE, Brain, Research, NIH, EFA, National Institute of Neurological Disorders and Stroke, Phase 3, Anemia, Interim, Private Securities Litigation Reform Act, Company, Week, Kidney, Solution, Arm, Risk, Mycosis, LNC, HIV, Infectious Diseases Society of America, Mortality, Partnership, Board, NYSE, Oligonucleotide, Person, Safety, Incidence, Survival rate, Technology, Form 10-K, National, Investor, Patient, Interval (mathematics), Enactment, Director, Consultant, Mucormycosis, BioNTech, NINDS, Conference, Organic acid, IV, Cohort, RNA transfection, Survival, MBA, Lung, National Institute, Death, Cryptococcosis, Sale, Vaccine, Hand, CM, Forward-looking statement, Management, Communications satellite, Fine chemical, Pharmaceutical industry, Stroke

In April 2022, Matinas and BioNTech entered an exclusive research collaboration centered on the combination of Matinas proprietary LNC platform technology and BioNTech mRNA formats.

Key Points: 
  • In April 2022, Matinas and BioNTech entered an exclusive research collaboration centered on the combination of Matinas proprietary LNC platform technology and BioNTech mRNA formats.
  • The Company will host a live conference call and webcast to discuss these results today, November 2, 2022, at 4:30 p.m.
  • Matinas BioPharma is a biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology.
  • Matinas BioPharmas product candidates are all in a development stage and are not available for sale or use.

Oncorus Reports Third Quarter 2022 Financial Results and Provides Business Updates

Retrieved on: 
Wednesday, November 2, 2022
Security (finance), CMC, Quality control, RNA, Annual report, Good manufacturing practice, U.S. Securities and Exchange Commission, Efficiency, SEC, Clinical trial, Cancer, GLOBE, Research, IND, Nasdaq, COVID-19, Immunotherapy, Public expenditure, Immune system, GMP, HSV, Safety, Good, Investment, LNP, Private Securities Litigation Reform Act, Neoplasm, Investor, Transgene, Patient, Nature Communications, RNA transfection, Vaccine, Pharmaceutical industry, Chemistry

We are preparing to announce further data from our ongoing clinical trial of ONCR-177 in the fourth quarter of this year.

Key Points: 
  • We are preparing to announce further data from our ongoing clinical trial of ONCR-177 in the fourth quarter of this year.
  • On track to report combination data and additional monotherapy data for ONCR-177 in the fourth quarter of 2022.
  • Research and development expenses for the quarter ended September 30, 2022 were $14.1 million compared to $11.3 million for the corresponding quarter in 2021.
  • General and administrative expenses for the quarter ended September 30, 2022 were $5.2 million compared to $5.4 million for the corresponding quarter in 2021.

Providence Therapeutics Appoints Judyanna Yu as Chief Financial Officer

Retrieved on: 
Wednesday, November 2, 2022
RNA transfection, Growth, RNA, Infection, Municipal government in Canada, Government, Cancer, GLOBE, Chartered Professional Accountant, Intention, COVID-19, Public expenditure, COO, Hilltop Holdings Inc., Al-Ameen Arts, Science and Commerce Degree College, Terminology, CFO, Corporate finance, VP, University, Vaccine, Observation, Therapy, Commerce, Patient, KPMG, CPA, Pharmaceutical industry, PTX-COVID19-B

CALGARY, Alberta, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Providence Therapeutics Holdings Inc. ("Providence"), a biopharmaceutical company developing messenger RNA (mRNA) vaccines and therapeutics, announces the appointment of Judyanna Yu, CPA, CA as chief financial officer (CFO).

Key Points: 
  • CALGARY, Alberta, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Providence Therapeutics Holdings Inc. ("Providence"), a biopharmaceutical company developing messenger RNA (mRNA) vaccines and therapeutics, announces the appointment of Judyanna Yu, CPA, CA as chief financial officer (CFO).
  • Judyannas extensive experience in global finance and operations will be critical as we enter our next phase of growth, said Brad Sorenson, chief executive officer of Providence Therapeutics.
  • Ms. Yu held CFO and VP of Finance roles at several other large private and public companies throughout her career.
  • Providence is a Canadian clinical-stage biotechnology company pioneering mRNA therapeutics and vaccines with operations in Calgary, Alberta and Toronto, Ontario.

Eloxx Pharmaceuticals Announces Opening of Clinical Trial Sites for Phase 2 Study of ELX-02 for the Treatment of Alport Syndrome

Retrieved on: 
Tuesday, November 1, 2022
RNA transfection, RNA, Plasma, RMAS, Science, CF, Mutation, SEC, Clinical trial, Cancer, GLOBE, Patient, Royal commission, Research, Eukaryotic ribosome, COVID-19, Allele, Disease, COL4A3, File, European Commission, Degenerative disease, Cystic fibrosis, Proteinuria, Kidney disease, Safety, Genetic disorder, Patent, Judgement, COL4A5, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NASDAQ, Private Securities Litigation Reform Act, Polycystic kidney disease, Hearing loss, FDA, Kidney, Food, Fast Track, Alport syndrome, Autosome, Forward-looking statement, Gene, COL4A4, Orphan, Pharmaceutical industry, Alport

Additional sites are expected to be opened and actively recruiting Alport patients in the coming weeks, said Sumit Aggarwal, President and Chief Executive Officer of Eloxx.

Key Points: 
  • Additional sites are expected to be opened and actively recruiting Alport patients in the coming weeks, said Sumit Aggarwal, President and Chief Executive Officer of Eloxx.
  • Alport patients with nonsense mutations have significantly worse clinical outcomes than other Alport patients and have no disease modifying treatment options.
  • This proof-of-concept clinical trial will include up to eight Alport syndrome patients with nonsense mutations in the second half of 2022.
  • Approximately 6% to 7% of Alport syndrome patients, or approximately 9,400 to 12,750 individuals, are estimated to have nonsense mutations.

Eterna Therapeutics Announces Research Collaboration to Develop Advanced Gene-Edited iPS Cell Therapies

Retrieved on: 
Tuesday, November 1, 2022
RNA transfection, Growth, Annual report, University, International, MD, Securities Exchange Act of 1934, Acquisition, Method, Immunity, Tissue, Hashimoto, MD Anderson Cancer Center, Cancer, GLOBE, Research, Palestinian National Interest Committee, U.S. Securities and Exchange Commission, Nasdaq, COVID-19, Novellus Systems, Securities Act of 1933, Cell, Terminology, Interim, Technology, AML, Cell engineering, Private Securities Litigation Reform Act, Company, Gene editing, IPS, Communication, Acute myeloid leukemia, Patient, Sumathi Best Television Current Reporting Award, SAN, Forward-looking statement, ERNA, Coronavirus Scientific Advisory Board (Turkey), Pharmaceutical industry, Vaccine, Leukemia, Eterna

We are excited to announce this research agreement to advance a central pillar of Eternas pipeline: allogeneic cell therapies for the treatment of cancer, said Matt Angel, Ph.D., Interim Chief Executive Officer of Eterna.

Key Points: 
  • We are excited to announce this research agreement to advance a central pillar of Eternas pipeline: allogeneic cell therapies for the treatment of cancer, said Matt Angel, Ph.D., Interim Chief Executive Officer of Eterna.
  • at the International Societyfor Cell & Gene Therapy 2021 Annual Meeting, and Eterna believes the advantages of its cells include exceptional manufacturing consistency due to the use of a highly characterized clonal iPS cell source.
  • Eternas completely non-viral approach to cell engineering avoids the risks inherent in other methods, said Roger Sidhu, M.D., Chief Medical Officer of Eterna.
  • Eterna is focused on developing advanced therapies using state-of-the-art mRNA cell engineering technology.

eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences

Retrieved on: 
Monday, October 31, 2022
Escape Room, RNA transfection, EIF4E, Therapy, Survival, Stri, MNK, Pfizer, Pembrolizumab, KRAS, Cancer, 4F, GLOBE, STRI, COVID-19, University of California, San Francisco, ER, University, NASDAQ, Investor, Protein, Patient, San Francisco, SAN, DARPA, NSCLC, EIF4A, Pharmaceutical industry, KICKSTART

A replay of the webcasts will be available for 30 days following the event.

Key Points: 
  • A replay of the webcasts will be available for 30 days following the event.
  • eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs.
  • eFFECTORs STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK).
  • eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E.

Early Is Good Raises $4 Million Seed Round from Social Capital

Retrieved on: 
Wednesday, November 2, 2022
Science, Nanotechnology, Research, General Health, Health, Medical Devices, Technology, Clinical Trials, Urine, MicroRNA, Bladder cancer, CEO, Hematuria, Nanotechnology, Urinary retention, Indiana Biosciences Research Institute, Biomarker, Cancer, Capital, Kidney, Blood, Bleeding, PPV, Disease, Silicon, RNA, EIG, Marie Cassidy, Technology, LDT, Prostate cancer screening, NPV, Social capital, Protein, Institute of Health and Biomedical Innovation, Perforation, Patient, Man, RNA transfection, Oncology, Infection, Cystoscopy, Diagnosis, Medical imaging, Tourism

Early is Good (EIG), a diagnostic solutions company focused on renal disease, announced it has closed a $4 million seed round from Social Capital, the Silicon Valley-based technology investment firm managed by Chamath Palihapitiya.

Key Points: 
  • Early is Good (EIG), a diagnostic solutions company focused on renal disease, announced it has closed a $4 million seed round from Social Capital, the Silicon Valley-based technology investment firm managed by Chamath Palihapitiya.
  • The funds will be used to complete clinical trials for EIGs first product, BCDx, a lab-developed test (LDT) for early bladder cancer detection.
  • Social Capital partner, Jay Zaveri, said, EIG hopes to give millions of people access to accurate, convenient, and early diagnoses for renal diseases.
  • Social Capital invests in smart, profit-minded opportunities and forward-thinking social investments that have the potential to shape a better future.

ReCode Therapeutics to Participate in Upcoming November Investor Conferences

Retrieved on: 
Wednesday, November 2, 2022
Health, Genetics, General Health, Research, Science, Pharmaceutical, Biotechnology, RNA transfection, Technology, Therapy, Recode, LNP, SORT, Company, Liver, Cystic fibrosis, Cell, Vaccine

ReCode Therapeutics , a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today that Company leadership will participate in two upcoming investor conferences in November:

Key Points: 
  • ReCode Therapeutics , a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today that Company leadership will participate in two upcoming investor conferences in November:
    ReCode Therapeutics is a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics.
  • ReCodes selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver.
  • The SORT LNP platform is the foundation for ReCodes pipeline of disease-modifying mRNA and gene correction therapeutics.
  • ReCode is leveraging its SORT LNP platform and nucleic acid technologies to expand its pipeline with therapeutics that use mRNA-mediated replacement and gene correction in target organs with precision targeting of disease-relevant cells.